Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00730379 | A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004) | PHASE1 | COMPLETED | 87 | — | — | Jul 1, 2008 | Nov 1, 2010 | Feb 10, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | ridaforolimus (MK8669) + dalotuzumab (MK0646) |
| Name | Type | Description |
|---|---|---|
| Comparator: ridaforolimus + dalotuzumab | DRUG | Starting dose of oral ridaforolimus is 10 mg/day, QD, for five days. Dose rising up to 40 mg/day, QD for five days. Dose range for intravenous dalotuzumab is 7.5 mg/kg/week, 10 mg/kg/week or 7.5 mg/kg/every 14 days. Dalotuzumab will be given as an IV infusion over 1 or 2 hour(s). |
Inclusion Criteria: * You must have confirmed metastatic or advanced cancer that has not responded to standard therapy or where standard therapy does not exist * In Part C, patients must have a diagnosis of advanced or metastatic colorectal adenocarcinoma or non-small cell lung cancer, and must hav...